ImmunoCellular (IMUC) Bullish View Reiterated at Maxim Group Amid ICT-107 Agreement
Tweet Send to a Friend
Maxim Group analyst Jason Kolbert reiterated a Buy rating and $3 price target on ImmunoCellular Therapeutics (NYSE: IMUC) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
